Viveve Medical Inc (NASDAQ: VIVE) is quickly increasing — its gross sales pressure, its remedy indications, its income and its fan base, in line with a bullish analyst.
Empire Asset Management Company’s Dr. Cathy Reese initiated protection on Viveve Medical with a Buy score and $10 worth goal.
The women’s health firm commercializes a know-how that makes use of radiofrequency to reinforce collagen manufacturing and tighten tissue.
The Viveve System, which acquired FDA advertising clearance for hemostasis in fall 2016, will quickly enter a second set of trials for vaginal laxity, a $7-billion international market alternative by Empire’s estimates. The research is meant to help appeals for a label enlargement to incorporate remedy of feminine sexual perform.
Viveve additionally plans to develop the system for stress urinary incontinence.
“Our expectations for revenue growth, positive future clinical data, label expansion(s) and increased physician and patient acceptance of the Viveve System support our belief that investors’ interest and confidence in this company will continually strengthen,” Reese stated in a notice. “Additionally, the aesthetic market does not seem to shy away from M&A activity.”
At the time of publication, Viveve shares have been buying and selling up 1.63 % at $four.36.
© 2018 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.